# Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)

> **NCT04639375** · PHASE4 · UNKNOWN · sponsor: **E-MO Biology Inc** · enrollment: 300 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** Vaccinated with polio vaccine (IPV)

## Key facts

- **NCT ID:** NCT04639375
- **Lead sponsor:** E-MO Biology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-15
- **Primary completion:** 2021-06-12
- **Final completion:** 2022-06-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04639375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04639375, "Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04639375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*